CONFIDENTIAL TREATMENT EPIX Medical, Inc. has requested that the marked portions of this document be accorded confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934.Loan Agreement • July 28th, 2003 • Epix Medical Inc • In vitro & in vivo diagnostic substances • New York
Final Version COLLABORATIVE RESEARCH AGREEMENT between EPIX and SCHERINGCollaborative Research Agreement • July 28th, 2003 • Epix Medical Inc • In vitro & in vivo diagnostic substances • New York
This COLLABORATIVE RESEARCH AGREEMENT (this “Agreement”) is entered into as of May 26, 2003 (the “Effective Date”), by and between Epix Medical, Inc., a Delaware corporation having its principal place of business at 71 Rogers Street, Cambridge, MA 02142-1118 USA (“EPIX”), and Schering Aktiengesellschaft, a German corporation having its principal place of business at 13342, Berlin, Germany (“SCHERING”). Each of SCHERING, EPIX and their respective Affiliates is sometimes referred to individually herein as a “Party” and collectively as the “Parties”.
Final Version THROMBUS DEVELOPMENT AGREEMENTThrombus Development Agreement • July 28th, 2003 • Epix Medical Inc • In vitro & in vivo diagnostic substances • New York
THIS THROMBUS DEVELOPMENT AGREEMENT dated as of May 26, 2003 (the “Agreement”) is made by and between EPIX Medical, Inc., a Delaware corporation having its principal place of business at 71 Rogers Street, Cambridge, Massachusetts 02142-1118 USA (“EPIX”), and Schering Aktiengesellschaft, a German corporation having its principal place of business at 13342, Berlin, Germany (“Schering”).
